For the millions of adults managing type 2 diabetes who have not yet been diagnosed with overt atherosclerotic disease, the question of whether aggressive lipid-lowering beyond statins is worthwhile has remained genuinely unresolved — until now. The VESALIUS-CV trial provides the most direct evidence to date that proactive PCSK9 inhibition in this population is more than theoretical benefit.
The VESALIUS-CV trial tested evolocumab, a PCSK9-inhibiting monoclonal antibody, against placebo in diabetic patients already on optimized lipid-lowering therapy but without established significant atherosclerosis. Over five years of follow-up, evolocumab meaningfully reduced the incidence of first major adverse cardiovascular events (MACE) — a composite endpoint typically encompassing cardiovascular death, myocardial infarction, and stroke. The trial specifically targets a primary-prevention-adjacent population, a cohort that has historically been underrepresented in PCSK9 inhibitor trials, which have largely enrolled high-risk secondary-prevention patients.
This finding carries notable clinical weight because it challenges the prevailing strategy of reserving PCSK9 inhibitors for patients with established cardiovascular disease. Diabetes itself confers cardiovascular risk comparable to established coronary disease in many risk models, yet therapeutic intensity has not always reflected that equivalence. That said, the correspondence published in JAMA rightly flags the importance of absolute risk reduction versus relative risk reduction — the lens through which cost-effectiveness and clinical policy are ultimately judged. When baseline event rates are lower in a primary-prevention cohort, even a substantial relative reduction may translate into a modest number-needed-to-treat, making blanket implementation economically contentious. Evolocumab carries significant annual cost, and the cost-per-QALY calculus in lower-risk diabetic patients without atherosclerosis is unlikely to be as favorable as in post-MI populations. This is an incrementally paradigm-shifting finding, but individualized risk stratification — not population-wide adoption — remains the prudent takeaway pending cost-effectiveness analyses.